SOLICITATION NOTICE
65 -- Notice of Intent to Sole Source to Antibodies Incorporated
- Notice Date
- 8/11/2023 6:22:36 AM
- Notice Type
- Presolicitation
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH - CC BETHESDA MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- 23-009593
- Response Due
- 8/16/2023 3:30:00 AM
- Archive Date
- 08/17/2023
- Point of Contact
- Shasheshe Goolsby, Phone: 301-827-4879
- E-Mail Address
-
shasheshe.goolsby@nih.gov
(shasheshe.goolsby@nih.gov)
- Description
- Title Mouse Monoclonal Projects for the Department of Perioperative Medicine of the NIH Clinical Center Product Service Code: 6550 NAICS Code: 325413 Place of Performance: Bethesda, MD 20892 USA POTS: 23-009593 Description This is a notice of intent, NOT a request for a quotation. A solicitation document will NOT be issued, and quotations will NOT be requested. The National Institutes of Health (NIH) intends to award a fixed price contract on a sole source basis to Antibodies Incorporated of Davis, California 95617 to provide highly sensitive and pan-species antibodies to two molecules in the pain pathway. The antibodies are used for detection of the receptor and the ion channel in tissue section. Effective detection of these molecules is mission critical. TRPVl and OPRMl are two genes that play important roles in pain sensation and pain control, respectively. TRPVl is a receptor that is activated by heat and other noxious stimuli, while OPRMl is the gene that codes for the opioid receptor and is the endogenous receptor for clinically-useful opioids. Opioids form the cornerstones of clinical pain management. TRPVl is involved in the perception of acute pain, such as the pain caused by a burn or a cut. It is also involved in the development of chronic pain, such as the pain caused by arthritis or cancer. OPRMl is involved in the modulation of pain, both through its direct effects in brain and through presynaptic inhibition of the release of neurotransmitters that can generally reduce pain. The proposed vendor, Antibodies Incorporated is the only vendor that can generate these antibodies that are highly unique to the Department of Perioperative Medicine. Antibodies Incorporated has been able to reduce the complexity of the design phase by working with previous information which makes it scientifically beneficial for the success of this project. � This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 � Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available.� Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government. Comments to this announcement, referencing this posting number, may be submitted to the Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention of Shasheshe Goolsby, Lead Contract Specialist, shasheshe.goolsby@nih.gov by August 16, 2023 6:30AM �EST. *** Please send your capability statements ONLY. This IS NOT a request for proposal. ***
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/f63c7894edc04005a9bc6e22809d6b1f/view)
- Place of Performance
- Address: Bethesda, MD 20814, USA
- Zip Code: 20814
- Country: USA
- Zip Code: 20814
- Record
- SN06787570-F 20230813/230811230101 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |